TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.

NCT00650832 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
334
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Tibotec Pharmaceuticals, Ireland